Brian Skorney
Stock Analyst at Baird
(3.37)
# 950
Out of 4,931 analysts
114
Total ratings
44.44%
Success rate
4.88%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $17.38 | +101.38% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $80.45 | +50.40% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $11.12 | +187.77% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $128.68 | +98.17% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $557.53 | +5.29% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $14.98 | +280.51% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $60.42 | -8.97% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $109.05 | -8.30% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $11.82 | +153.81% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.44 | +1,044.95% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $7.02 | +184.90% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.31 | +480.05% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.05 | +227.87% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $282.77 | -23.97% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $126.96 | +41.78% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.55 | +515.38% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $27.35 | +126.69% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.76 | +402.58% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $33.00 | +90.91% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $375.39 | -13.42% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $15.65 | -36.10% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.84 | +9,407.04% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.11 | +92.93% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.70 | +17,547.06% | 3 | May 7, 2018 |
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $17.38
Upside: +101.38%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $80.45
Upside: +50.40%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $11.12
Upside: +187.77%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $128.68
Upside: +98.17%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $557.53
Upside: +5.29%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $14.98
Upside: +280.51%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $60.42
Upside: -8.97%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $109.05
Upside: -8.30%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.82
Upside: +153.81%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.44
Upside: +1,044.95%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $7.02
Upside: +184.90%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.31
Upside: +480.05%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.05
Upside: +227.87%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $282.77
Upside: -23.97%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $126.96
Upside: +41.78%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.55
Upside: +515.38%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $27.35
Upside: +126.69%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.76
Upside: +402.58%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $33.00
Upside: +90.91%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $375.39
Upside: -13.42%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $15.65
Upside: -36.10%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.84
Upside: +9,407.04%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.11
Upside: +92.93%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.70
Upside: +17,547.06%